Characteristics of drug resistance in HIV-1 CRF55_01B from ART-experienced patients in Guangdong, China.
PMID: 32300784
2020
The Journal of antimicrobial chemotherapy
Abstract: Among DRMs, M184V (43.83%) was the most frequent NRTI DRM, followed by K65R (23.46%), and V179E (98.77%) was the most frequent NNRTI DRM, followed by K103N (47.53%) and Y181C (14.81%).
HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform.
Abstract: NRTI and NNRTI associated dominant mutations were M184I/V and K103 N.High-level resistance to lamivudine (3 TC) and Emtricitabine (FTC) were detected in 34.3% of patients while 53.1% were resistant to Efavirenz (EFV) and Nevirapine (NVP).
HIV-1 Drug Resistance in ART-Naive Individuals in Myanmar.
Discussion: Another survey focusing on Burmese individuals staying in Dehong reported that M184V, K103N/KN, and T74S/ST were the major SDRMs associated with VF.
Discussion: Furthermore, we found that the major NNRTI-related SDRMs were K101P, K103N, V106A, E138A, Y181C, and Y188H, and the major NRTI-related SDRMs were L74V/I and M184V.
Discussion: Some SDRMs, including NRTI-related mutations (M41L, D6
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
Discussion: Additional support for this hypothesis comes from two retrospective cohort studies in which a historical plasma genotype detecting the M184V mutation was not predictive of virologic failure in participants switching to lamivudine- based dual therapies with either a protease inhibitor or an integrase inhibitor.
Discussion: Another study reported lower viral rebound in persons harboring the M184V who received lamivudine monotherapy compared to patients interrupting treatment.
Discussion: dual therapy with either boosted protease inhibitor or integrase inhibitor plus lamivudine in persons with past M184V demonstrated only a statistically higher risk of virological failure for those with a viral suppression equal or under three yea
High Efficacy of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with Suppressed HIV and Preexisting M184 V/I.
PMID: 32413134
2020
The Journal of antimicrobial chemotherapy
Abstract: A plasma historical genotypic report (HGR) showing the presence of M184V/I was required for all participants and proviral HIV DNA analysis was conducted prior to enrolment.
Abstract: BACKGROUND: The M184V/I reverse transcriptase mutation, which confers major resistance to lamivudine and emtricitabine, is still quite frequent in people living with HIV.
Abstract: CONCLUSIONS: Our results suggest that undetected M184V/I should be considered when switching virologically suppressed patients to new regimens, particularly two-drug lamivudine- or emtricitabine-containing combinations.
Abstract: Differential detection of M184V/I was not associated with timing differences between the HGR and proviral HIV DNA sampling, the overall duration of ART, or CD4 cell counts and HIV
Virologic failure after 48 weeks of raltegravir-based regimen in low HIV-1 incidence setting.
Abstract: M184V mutation associated with high level resistance to lamivudine and emtricitabine was detected in six out of seven patients.
Result: Among patients with M184V mutation, two had mutations at position 138 of reverse transcriptase that is associated with low-level resistance to the NNRTI, rilpivirine, and three had major mutations (Y143C, N155H, T66I, G118R, E138K) conferring high level resistance to RAL (Table 2).
Result: Furthermore, accessory mutations potentially associated with low level resistance to InSTIs accompanied the reve
Table: M184V
Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi.
Abstract: In one case, we detected an NRTI resistance mutation (M184V), in combination with multiple NNRTI resistance mutations.
Result: In one case, we detected an additional NRTI drug resistance mutation (M184V) (Table 2).
Table: M184V
High Levels of Acquired HIV Drug Resistance Following Virological Nonsuppression in HIV-Infected Women from a High-Risk Cohort in Uganda.
PMID: 32475121
2020
AIDS research and human retroviruses
Abstract: The mutation K103N was detected in 62.5% (30/48) of participants, 41.7% (20/48) had M184V/I, 14.6% had K65R, and 12.5% (6/48) had thymidine analog mutations (TAMs).
Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries.
PMID: 32522826
2020
Journal of clinical microbiology
Abstract: In a cross-sectional study (June 2018 to September 2019), we evaluated the diagnostic accuracy of a simple and rapid HIVDR assay (the pan-degenerate amplification and adaptation [PANDAA] assay targeting the mutations K65R, K103NS, M184VI, Y181C, and G190A) compared to Sanger sequencing and next-generation sequencing (NGS).
Abstract: PANDAA showed strong agreement with Sanger sequencing for K65R, K103NS, M184VI, and G190A (kappa > 0.85) and substantial agreement for Y181C (kappa = 0.720).
HIV-1 Genetic Diversity and High Prevalence of Pretreatment Drug Resistance in Tianjin, China.
PMID: 32539490
2020
AIDS research and human retroviruses
Abstract: The most frequent mutation pattern against NNRTIs was V179D/E/T (6.9%, 21/305), with M184V (1.0%, 3/305) and K65R (1.0%, 3/305) against nucleoside RT inhibitors (NRTIs).
HIV mutation literature information.
PMID: 
2020
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT